Cargando…
Comparative effectiveness of bisphosphonate treatments for the prevention of re-fracture in glucocorticoid-induced osteoporosis: protocol for a systematic review and meta-analysis
BACKGROUND: Long-term usage of glucocorticoids results in a loss of bone mass and a higher risk of fracture, and the most common cause of secondary osteoporosis is glucocorticoid-induced osteoporosis (GIOP). For preventing GIOP, bisphosphonate (BP) is widely used. However, analysis on BP’s effect on...
Autores principales: | Chu, Hongmin, Jang, Bo-Hyoung, Kim, GaYoon, Bae, Seowoo, Lee, Hyeju, Nam, Seonghee, Ahn, Jeonghoon |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9516213/ https://www.ncbi.nlm.nih.gov/pubmed/36167395 http://dx.doi.org/10.1136/bmjopen-2022-062537 |
Ejemplares similares
-
Bisphosphonates and glucocorticoid-induced osteoporosis: cons
por: Lems, Willem F., et al.
Publicado: (2015) -
Subtrochanteric Femoral Insufficiency Fracture in Woman on Bisphosphonate Therapy for Glucocorticoid-Induced Osteoporosis
por: Bush, Lisabeth A., et al.
Publicado: (2016) -
Once-weekly teriparatide improves glucocorticoid-induced osteoporosis in patients with inadequate response to bisphosphonates
por: Seno, Takahiro, et al.
Publicado: (2016) -
Effects of denosumab versus teriparatide in glucocorticoid-induced osteoporosis patients with prior bisphosphonate treatment
por: Hirooka, Yasuaki, et al.
Publicado: (2020) -
Influence on persistence and adherence with oral bisphosphonates on fracture rates in osteoporosis
por: Höer, Ariane, et al.
Publicado: (2009)